INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 135 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2018. The put-call ratio across all filers is 0.27 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $1,367,403 | -16.3% | 19,965 | -15.5% | 0.00% | 0.0% |
Q1 2024 | $1,634,574 | +5.4% | 23,621 | +9.1% | 0.00% | -20.0% |
Q4 2023 | $1,551,217 | +61.4% | 21,659 | +17.4% | 0.01% | +66.7% |
Q3 2023 | $961,061 | -17.5% | 18,450 | +0.3% | 0.00% | 0.0% |
Q2 2023 | $1,164,645 | +24.0% | 18,393 | +6.0% | 0.00% | 0.0% |
Q1 2023 | $939,448 | -9.5% | 17,349 | -11.6% | 0.00% | -25.0% |
Q4 2022 | $1,038,396 | +23.6% | 19,622 | +8.9% | 0.00% | +33.3% |
Q3 2022 | $840,000 | -16.6% | 18,025 | +2.2% | 0.00% | 0.0% |
Q2 2022 | $1,007,000 | -33.2% | 17,638 | -28.4% | 0.00% | 0.0% |
Q1 2022 | $1,507,000 | +7.0% | 24,633 | -8.5% | 0.00% | 0.0% |
Q4 2021 | $1,408,000 | +42.8% | 26,913 | +1.8% | 0.00% | 0.0% |
Q3 2021 | $986,000 | -26.6% | 26,437 | -19.7% | 0.00% | -25.0% |
Q2 2021 | $1,344,000 | +37.0% | 32,924 | +13.8% | 0.00% | +33.3% |
Q1 2021 | $981,000 | +13.9% | 28,924 | +6.9% | 0.00% | 0.0% |
Q4 2020 | $861,000 | +77.9% | 27,061 | +43.5% | 0.00% | +50.0% |
Q3 2020 | $484,000 | +4.3% | 18,858 | +4.2% | 0.00% | 0.0% |
Q2 2020 | $464,000 | +149.5% | 18,094 | +49.7% | 0.00% | +100.0% |
Q1 2020 | $186,000 | -69.9% | 12,088 | -32.8% | 0.00% | -66.7% |
Q4 2019 | $617,000 | +314.1% | 17,988 | -10.1% | 0.00% | +200.0% |
Q3 2019 | $149,000 | -44.8% | 20,010 | -4.0% | 0.00% | -50.0% |
Q2 2019 | $270,000 | -5.9% | 20,835 | -11.7% | 0.00% | 0.0% |
Q1 2019 | $287,000 | +8.3% | 23,594 | +1.4% | 0.00% | 0.0% |
Q4 2018 | $265,000 | -56.1% | 23,276 | -16.2% | 0.00% | -50.0% |
Q3 2018 | $603,000 | +18.2% | 27,791 | -3.8% | 0.00% | +33.3% |
Q2 2018 | $510,000 | -20.9% | 28,884 | -5.8% | 0.00% | -25.0% |
Q1 2018 | $645,000 | +24.8% | 30,661 | -14.1% | 0.00% | 0.0% |
Q4 2017 | $517,000 | +22.2% | 35,705 | +33.3% | 0.00% | 0.0% |
Q3 2017 | $423,000 | +34.7% | 26,776 | +6.0% | 0.00% | +33.3% |
Q2 2017 | $314,000 | -28.5% | 25,269 | -6.6% | 0.00% | -40.0% |
Q1 2017 | $439,000 | -14.8% | 27,045 | -20.7% | 0.01% | -16.7% |
Q4 2016 | $515,000 | +146.4% | 34,098 | +778.6% | 0.01% | +100.0% |
Q4 2015 | $209,000 | – | 3,881 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
DCF Advisers, LLC | 375,000 | $15,308,000 | 5.42% |
SILVERARC CAPITAL MANAGEMENT, LLC | 113,258 | $4,623,000 | 2.06% |
Tri Locum Partners LP | 150,783 | $6,155,000 | 2.02% |
COOPER/HAIMS ADVISORS, LLC | 61,116 | $2,495,000 | 1.64% |
Vantage Consulting Group Inc | 226,670 | $9,252,000 | 1.61% |
Nicholas Investment Partners, LP | 598,261 | $24,421,000 | 1.53% |
Bellevue Group AG | 3,609,919 | $147,357,000 | 1.44% |
GENERAL AMERICAN INVESTORS CO INC | 350,804 | $14,320,000 | 1.20% |
Rhenman & Partners Asset Management AB | 429,728 | $17,541,000 | 1.19% |
WASATCH ADVISORS LP | 6,506,789 | $265,607,000 | 1.08% |